TWD 75.9
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 616.93 Million TWD | 56.81% |
2022 | 393.43 Million TWD | 22.47% |
2021 | 321.26 Million TWD | 18.81% |
2020 | 270.39 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 535.63 Million TWD | -13.18% |
2024 Q2 | 593.11 Million TWD | 10.73% |
2023 FY | 616.93 Million TWD | 56.81% |
2023 Q3 | 538.34 Million TWD | 2.52% |
2023 Q2 | 525.1 Million TWD | 58.17% |
2023 Q1 | 331.98 Million TWD | -15.62% |
2023 Q4 | 616.93 Million TWD | 14.6% |
2022 Q4 | 393.43 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 32.214% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | -118.354% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | -4.567% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 81.687% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 82.994% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 90.722% |
Center Laboratories, Inc. | 6.78 Billion TWD | 90.909% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | -283.064% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 30.851% |
InnoPharmax Inc. | 48.64 Million TWD | -1168.129% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | -92.195% |
Excelsior Biopharma Inc. | 472.87 Million TWD | -30.464% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 19.447% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | -119.642% |
UniPharma Co., Ltd. | 37.4 Million TWD | -1549.507% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 39.238% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | -710.803% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | -65.01% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -1140.788% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | -467.283% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | -361.686% |